Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer

Neele Wüstmann1, Julissa Reimann1, Julia Vieler1

  • 1Department of Urology, University Hospital Muenster, Germany.

Insights

This study investigated androgen receptor splice variants (AR-V) in prostate cancer, finding no distinct AR-V transcriptome driving treatment resistance. Further research is needed to understand AR-V

Area of Science:

  • Molecular Oncology
  • Prostate Cancer Research
  • Gene Expression Analysis

Background:

  • Androgen receptor (AR) signaling is crucial in prostate cancer progression.
  • AR splice variants (AR-Vs) are implicated in resistance to androgen-deprivation therapies (ARTAs).
  • The specific role of AR-Vs in treatment resistance and tumor progression remains incompletely understood.

Purpose of the Study:

  • To comprehensively analyze AR-V specific target gene expression in a model simulating co-occurrence of full-length AR (AR-FL) and AR-Vs.
  • To investigate the functional activity of clinically relevant AR-Vs (AR-V3, AR-V7, AR-V9) in prostate cancer cells.
  • To challenge the hypothesis of an AR-V specific transcriptome driving treatment resistance.

Main Methods:

  • Transfection of AR-FL and AR-V variants (AR-V3, AR-V7, AR-V9) into AR-negative PC-3 prostate cancer cells.
  • RNA sequencing to analyze differential gene expression.
  • Immunofluorescence and luciferase assays to determine protein activity.
  • Analysis of published target genes and clinical survival data.

Main Results:

  • RNA sequencing revealed minimal differences in gene expression between AR-FL and co-expressing AR-V cells.
  • AR-V7 exhibited constitutive activity, AR-V9 showed ambivalent activity, AR-V3 was inactive, and AR-FL was hormone-dependent.
  • Upregulation of EDN2 and FKBP5 was observed, but clinical analysis showed no significant impact of AR-Vs on patient survival.

Conclusions:

  • The study challenges the existence of a distinct AR-V specific transcriptome driving treatment resistance and tumor progression.
  • The molecular mechanisms by which AR-V proteins contribute to resistance to ARTA treatment require further investigation.
  • Clinical outcomes did not correlate with the presence of AR-Vs in this study cohort.

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.4K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
24.7K
What is Gene Expression?01:36

What is Gene Expression?

A gene is a stretch of DNA that serves as the blueprint for functional RNAs and proteins. Since DNA is comprised  of nucleotides and proteins are comprised of amino acids, a mediator is required to convert the information encoded in DNA into proteins. This mediator is the messenger RNA (mRNA). mRNA copies the blueprint from DNA by a process called transcription. In eukaryotes, transcription occurs in the nucleus by complementary base-pairing with the DNA template. The mRNA is then...
11.0K